Because COVID-19 is known to raise the wards for dangerous blood clots, blood thinners have quickly become part of routine care for many hospitalized patients.
But three clinical trials testing total doses of these drugs in COVID-19 patients have now halted the recruitment of critically ill patients because the medications could do more. cron na math.
According to experts at the U.S. National Institutes of Health (NIH), the detection is limited to COVID-19 patients who are so ill that they require care in the intensive care unit (ICU).
Based on trial findings, and working on the recommendations of board of directors accused of patient safety in clinical trials, “all trial sites have suspended registration of the most critical patients in the hospital with COVID -19, “the NIH said in a statement released Tuesday.
“Registration continues for moderately ill COVID-19 patients in the trials,” the NIH said, as benefits may still outweigh risks for patients who do not require ICU care.
According to the NIH, results to date from all three trials show that full-dose blood thinners do No they appear to reduce the need for organ support in critically ill, adult COVID-19 patients in intensive care.
On the other hand, there may be harm: Increased swelling is a problem of full-dose use of blood thinners.
One doctor on the face of pandemic agreed that there are risks against full-dose doses.
“While lower doses of blood thinners may be helpful in the treatment and prevention of blood clots in patients with moderate to severe COVID-19, higher doses may be associated with harm such as resulting in an increased risk for bleeding – which can affect the GI tract, lungs and brain, “said Dr. Robert Glatter, an emergency medical physician at Lenox Hill Hospital in New York City.” bleaching can be fatal if not quickly proven and treated. “
Further analyzes of the data will be available as soon as possible, the NIH said.
All three experiments are taking place on four continents. Each compares the use of full doses of blood thinners versus the use of lower doses, which are often used to prevent blood clots in hospitalized patients.
These tests were launched because health care providers have noticed that many COVID-19 patients, including those who died from the disease, developed blood clots all over their bodies, even in their smallest blood vessels. This abnormal clotting can cause serious problems such as lung failure, heart attack and stroke, according to the NIH.
“At the recommendation of the boards of directors, patients who do not require ICU care at the time of enrollment will remain enrolled in the trial,” the NIH said.
“Whether full-dose use compared to low-dose blood thinners leads to better outcomes in hospitalized patients with less severe COVID-19 infection remains an important question. Patients who need full-dose blood thinners for other medical indications were included in these tests, “the NIH noted.
Dr. Teresa Murray Amato is chair of emergency medicine at the Long Island Jewish Forest Mountains, also in New York City. Responding to NIH’s notice, she said, “As we learn more about the COVID-19 virus, we continue to study medical treatment.”
She confirmed that full-dose blood thinners may still play a role in the care of hospital patients who do not require ICU care.
“The study continues for less serious patients in the hope that we will continue to develop safe and effective treatments,” Amato said.
Find out more
The U.S. Centers for Disease Control and Prevention has more on COVID-19.
SOURCE: Robert Glatter, MD, emergency medicine physician, Lenox Hill Hospital, New York City; Teresa Murray Amato, MD, chair, emergency medicine, Long Island Jewish Forest Mountains, New York City; US National Institutes of Health, press release, December 22, 2020
Copyright 2020 HealthDay. All rights reserved.
